This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H. Lundbeck A/S
Drug Names(s): vigabatrin
Description: Sabril is an irreversible GABA-transaminase inhibitor, the enzyme responsible for the catabolism of GABA. This produces a two- to three-fold increase in brain levels of GABA, a neurotransmitter that inhibits brain activity. While Sabril is an analog of GABA, it is not a receptor agonist.
The compound was introduced in Europe in the 1980s as an anticonvulsant, but fell out of favor (and was not approved in the US) due to visual toxicity. However, families in the US have imported the drug for patients with infantile spasms.
In April 2004, OVATION Pharmaceuticals announced that it acquired from Aventis in a cash transaction the exclusive North American rights for Sabril. Financial terms were not disclosed. OVATION will assume all responsibility for Sabril in North America, including clinical development, regulatory approval, and commercialization.
In May 2004, Paladin Labs entered into an exclusive Canadian distribution agreement with Ovation for Sabril. Under the terms of the agreement, Paladin will assume responsibility for customer service, logistics, credit and collection, and pharmacovigilance support in return for a modest distribution fee. The responsibility of marketing and promotion of these brands in Canada will remain with Ovation.
In February 2009, H. Lundbeck and Ovation Pharmaceuticals announced that they entered into a definitive transaction agreement under which Lundbeck will acquire Ovation in an all cash transaction valuing...See full deal structure in Biomedtracker
Pink Sheet Ovation acquires Aventis CNS drugs
Pink Sheet In Brief: Hoechst Marion Roussel Sabril
Additional information available to subscribers only: